Healthcare

Healthcare

Companies advancing medical treatments and health services

0 items
Valuation
Price
TXG
10x Genomics, Inc. Class A Common Stock
TXG
61
$1.99B
-
$15.86
-0.38%
FDMT
4D Molecular Therapeutics, Inc. Common Stock
FDMT
33
$625.63M
-
$11.60
5.21%
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock
SXTP
61
$3.47M
-
$0.83
-3.94%
ETNB
89bio, Inc. Common Stock
ETNB
50
$2.20B
-
$14.95
0.10%
ABBV
ABBVIE INC.
ABBV
22
$401.99B
0.76%
$223.67
-1.69%
ABVC
ABVC BioPharma, Inc. Common Stock
ABVC
11
$49.33M
-
$2.06
1.72%
ACIU
AC Immune SA Common Stock
ACIU
22
$403.24M
-
$3.31
1.54%
ACAD
ACADIA Pharmaceuticals Inc. Common Stock
ACAD
77
$4.61B
-
$27.10
-1.72%
ADCT
ADC Therapeutics SA
ADCT
38
$521.52M
-
$3.97
-5.23%
ADMA
ADMA Biologics Inc Common Stock
ADMA
55
$4.70B
-
$19.22
-2.84%
AIM
AIM ImmunoTech Inc.
AIM
11
$3.77M
-
$1.44
3.03%
ALTS
ALT5 Sigma Corporation Common Stock
ALTS
44
$164.78M
-
$1.30
-1.11%
ALXO
ALX Oncology Holdings Inc. Common Stock
ALXO
27
$75.91M
-
$1.43
0.71%
AMN
AMN Healthcare Services
AMN
33
$614.24M
-
$16.03
-1.09%
ANTX
AN2 Therapeutics, Inc. Common Stock
ANTX
44
$32.06M
-
$1.15
1.71%
ANIP
ANI Pharmaceuticals, Inc.
ANIP
50
$1.83B
-
$81.09
-0.69%
SPRY
ARS Pharmaceuticals, Inc. Common Stock
SPRY
44
$1.05B
-
$10.66
0.66%
AARD
Aardvark Therapeutics, Inc. Common Stock
AARD
44
$315.06M
-
$13.92
-4.08%
ABCL
AbCellera Biologics Inc. Common Shares
ABCL
50
$1.05B
-
$3.44
-1.57%
ABT
Abbott Laboratories
ABT
66
$223.39B
0.49%
$126.66
-1.26%
Get professional financial guidance

Schedule your free first call with a financial adviser on CUSP
*T&Cs apply

*T&Cs apply

Fees SchedulePrivacy & Cookies PolicyTerms & Conditions

Disclaimer

CUSP Limited is a DIFC-incorporated and DFSA-regulated company with a Category 4 license, including Islamic and Retail Endorsement. We are authorised to advise on financial products and arrange deals in investments.

Any information presented here is of a general nature and does not take into account your personal circumstances or financial objectives. All materials used in these communications are for marketing purposes of the CUSP Application; none are meant to offer to sell, a solicitation of an offer to buy, or a recommendation of any security or other financial instrument. They are not intended to provide investment, other financial, legal, tax, or other advice.

Investments involve market volatility, possible capital loss, liquidity limits, and regulatory changes.

Past performance of financial products is not a reliable indicator of future results. The value of investments can go down as well as up, and you may lose all or part of your capital. No content from CUSP should be understood as guaranteeing returns, offering risk-free investments, or promising wealth outcomes.

This material is intended for DFSA-defined Retail and/or Professional Clients. If you are unsure of your classification or eligibility, please contact us at [email protected].

For interested persons, certain products and services are structured according to Islamic principles and approved under our DFSA-issued Islamic Endorsement.